Target Practice in IBD

Inflammatory Bowel Disease

Program Information

Target Audience:

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

After completing this program, participants should be better able to:

Summarize current recommendations for selecting and assessing therapeutic targets in patients with Inflammatory Bowel Disease

Describe the evidence regarding clinical, endoscopic and histological healing in Inflammatory Bowel Disease

Differentiate current biologic and small molecule therapies used in Inflammatory Bowel Disease with respect to mechanisms of action, efficacy, and safety


For more information, visit www.GiHealthFoundation.org, email info@GiHealthFoundation.org or call 877-782-4532.

Provided by


Supported by an educational grant from
Janssen Biotech, Inc.

IN CASE YOU MISSED OUR LIVE INTERNET BROADCAST!

Post-DDW ®
Highlights

(Select a speaker to view their full bio)

STEPHEN B. HANAUER, MD, FACG (CHAIR)
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

GARY R. LICHTENSTEIN, MD
University of Pennsylvania
Philadelphia, Pennsylvania

UMA MAHADEVAN, MD
UCSF Center for Colitis and Crohn's Disease
San Francisco, California

WILLIAM J. SANDBORN, MD
UC San Diego Health System
La Jolla, California

AGENDA
Welcome, Introductions and Post DDW ® Update
IBD Therapy: Current and Future Treatment Targets in Clinical Practice
Current Therapeutic Agents: Mechanism of Action and Target Achievement
IBD Therapeutic Treatment Decisions: Factors Influencing Therapeutic Choice
Panel Discussion and Q&A
Closing Remarks

Back to Overview
STEPHEN B. HANAUER, MD, FACG (CHAIR)
Northwestern University Feinberg School of Medicine
Clifford Joseph Barborka Professor of Medicine
Medical Director, Digestive Diseases Center
Chicago, Illinois
Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs.

Dr. Hanauer is a board-certified internist and gastroenterologist, and is the Clifford Joseph Barborka Professor of Medicine and medical director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine. Dr. Hanauer is a fellow and past president of the American College of Gastroenterology (ACG) and the former chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. He is also a prior member of the Gastroenterology Specialty Board of the American Board of Internal Medicine and is a member and former-chairman of the International Organization for Inflammatory Bowel Disease. Among his many honors, Dr. Hanauer received the ACG’s Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology and the Janssen Award for Clinical Excellence. He has served as a member of the U.S. FDA Gastrointestinal Drugs Advisory Committee since 1987. He chaired the committee from 1998-2000, and he presently serves the Center for Drug Development and Research as a Special Consultant defining new guidelines for the clinical evaluation of IBD patients. In February 2020, he received the "Great Teachers" Award from the National Institute of Health (NIH).


Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of many of the leading IBD therapies, including: Uceris®, Asacol HD®, Remicade®,Humira®, and Entyvio®.


Dr. Hanauer has authored over 450 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He is the former-editor-in-chief of Nature Clinical Practice Gastroenterology & Hepatology and currently serves as associate editor (IBD) of Clinical Gastroenterology and Hepatology. Dr. Hanauer is also a member of the editorial boards of other journals, most notably the American Journal of Gastroenterology and Inflammatory Bowel Diseases.


Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 1999, he was named the Joseph B. Kirsner Chair in Medicine and was designated chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago. In 2014, Dr. Hanauer was named the medical director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University's Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.


SPEAKER DISCLOSURES:
Clinical Research: AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfize, Prometheus, Receptos, Takeda, UCB
Consultant: AbbVie, Allergan, Amgen, Arena, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, Tigenex, UCB, VHsquared
DSMB: Arena, Bristol-Myers Squibb
Speaker: AbbVie, Janssen, Takeda

Back to Overview
Gary R. Lichtenstein, MD, FACP, FACG, AGA
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania
 

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease Program in the Department of Medicine’s Division of Gastroenterology at the Hospital of the University of Pennsylvania, and a professor of medicine at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia, Pennsylvania.


Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina. He also completed a fellowship in gastroenterology at the Hospital of the University of Pennsylvania in the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease, and he has received numerous research grants focusing on these areas. Dr. Lichtenstein has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn’s disease.


A fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology (ACG), Dr. Lichtenstein has been listed in Best Doctors in America (inflammatory bowel disease), and has served as medical secretary for the gastroenterology section of the American Board of Internal Medicine. He holds membership and committee positions in many professional societies at a national level, including the AGA, where he has served as chair of the Clinical Practice Updates Committee and as vice chair of the Clinical Practice Updates Committee and the Practice Management Economics Committee; the American Society for Gastrointestinal Endoscopy, where he has served on the Committee on Training; and the ACG, where he has served on the Educational Affairs Committee, the programs committee, and the nominations committee, as well as recently serving as a member of the Research Committee.


Dr. Lichtenstein has also been the chair of the abstract review committee for inflammatory bowel disease for the ACG. He is a member of the Crohn’s & Colitis Foundation of America (CCFA), where he served at the national level as the chair of the Membership Committee of the Clinical Research Alliance, on the national grants review committee, and on the national physician education committee. In addition, he is a longstanding member of the American College of Physicians and the American Medical Association. Dr. Lichtenstein has received numerous awards in the University of Pennsylvania Health System, including the Louis Duhring Outstanding Clinical Specialist Award, the Lindback Award for Distinguished Teaching (the top teaching award at the University of Pennsylvania), and the Penn Pearls Award, the medical school teaching award. He has received the Department of Medicine Housestaff teaching award, the Donald B. Martin Teaching Service Award, and the Gastroenterology Division Sidney Cohen Teaching Award for Faculty. He is listed in The Best Doctors in America (inflammatory bowel disease) and in Philadelphia Magazine as being among the top gastroenterologists for the elderly in Philadelphia and among the top gastroenterologists in Philadelphia (special focus: inflammatory bowel disease). He is also the recipient of the CCFA Physician of the Year Award (Philadelphia/Delaware Valley Chapter). In addition to having served on the editorial board of the journals Gastroenterology, the American Journal of Gastroenterology, Inflammatory Bowel Diseases, the World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein has served as a former writer of selected summaries in the journal Gastroenterology, as the section editor of selected summaries, and as the section editor of print and media reviews in gastroenterology for a five-year term. He has also served and currently serves as a reviewer for such journals as the New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, the Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology, and the Journal of Clinical Gastroenterology. He is executive editor of the newly PubMed-indexed journal Gastroenterology & Hepatology, and serves as associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and the Journal of Clinical Investigation. He is currently assistant editor in chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international level, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles, chapters, letters, and editorials. He has presented over 250 abstracts and edited 18 books. He has lectured at a national and international level at more than 300 invited conferences, symposia, and institutional grand rounds.


 
SPEAKER DISCLOSURES:
Author Honorarium: Up-To-Date
Book Royalty: SLACK, Inc
Consultant: Abbvie, CellCeutrix, Celgene, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Eli Lilly, American Regent, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, UCB
DSMB: Eli Lilly
Editor (Honorarium): Gastroenterology and Hepatology (Gastro-Hep Communications), Springer Science and Business Media
Funding to the University of PA (IBD Fellow Education): Janssen Orthobiotech, Pfizer Pharmaceuticals, Takeda
Honorarium for associate editor of the American Journal of Gastroenterology: American College of Gastroenterology
Honorarium (CME Program): American Regent, Merck, Romark
Research: Celgene, UCB, Janssen Orthobiotech
Royalty for writing textbook: "Clinical Management of Ulcerative Colitis": Professional Communications, Inc.

Back to Overview
UMA MAHADEVAN, MD
Professor of Medicine
University of California, San Francisco
Co-Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, California
 

Uma Mahadevan completed a medical degree at the State University of New York in Brooklyn. She completed a residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF) and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as professor of medicine at UCSF, clinical services Chief for gastroenterology, and co-director of the UCSF Center for Colitis and Crohn’s Disease, and director of the IBD Fellowship.


Certified by the American Board of Internal Medicine as a diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she is a chair for the Clinical Immunology, Microbiology and Inflammatory Bowel Disease (IMIBD) Section and chair of the AGA National IBD Parenthood initiative. She is a Fellow of the American College of Gastroenterology and serves on the Educational Affairs Committee and as a member of the Advanced IBD fellow Curriculum Committee. She is currently chair of the Crohns Colitis Foundation Clinical Research Grants committee, a member of their National Scientific Advisory Committee and Taskforce on Women in IBD, and co-chair of the annual Crohn’s Colitis Congress.


Dr. Mahadevan is a special section editor for the journal Gastroenterology and an editorial board member and reviewer for several journals. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, the American Journal of Gastroenterology, Inflammatory Bowel Diseases, and Gut along with several book chapters.


Dr. Mahadevan specializes in the treatment of ulcerative colitis, Crohn’s disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn’s disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and the impact of nutritional interventions in the management of IBD.


SPEAKER DISCLOSURES:
Consultant: Abbvie, Janssen, Gilead, Takeda, BMS
Research Grant: Pfizer, Celgene, Genentech

Back to Overview
WILLIAM SANDBORN, MD
Professor of Medicine
Chief, Division of Gastroenterology
Vice Chair for Clinical Operations Department of Medicine
Director, UCSD IBD Center, UC San Diego Health System
La Jolla, California

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to professor of medicine, vice chairman of the Division of Gastroenterology and Hepatology, and associate dean of research for Intellectual Property and Industry Relations. In 2011, he became a tenured professor of medicine and adjunct professor of surgery at the University of California San Diego and director of the IBD Center and chief of the Division of Gastroenterology for the UC San Diego Health System. He is vice chair for clinical operations for the Department of Medicine, and a member of the UC San Diego Health Physicians Group Board (which oversees the clinical practice for the entire UC San Diego Health System). Dr. Sandborn has published over 776 peer-reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 129. He is a member of the editorial board for the New England Journal of Medicine. In 2019, he was awarded the Sherman Prize for his work in inflammatory bowel disease. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.

 
SPEAKER DISCLOSURES:
Consulting Fees: Abbive, Allergan, Amgen, Arena Pharmaceuticals, Avexegen, Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals
Research Grants: Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly, Celgene/Receptos, Pfizer, Prometheus Laboratories (now Prometheus Biosciences)
Stock or Stock Options: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences
Spouse:
Consultant: Opthotech, Progenity
Employee: Oppilan Pharma, Escalier Biosciences, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Ventyx Biosciences, Vimalan Biosciences,
Stock Options: Opthotech, Progenity, Oppilan Pharma, Escalier Biosciences, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Ventyx Biosciences, Vimalan Biosciences

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.